Perpetual Ltd’s Alnylam Pharmaceuticals ALNY Stock Holding History

Perpetual Ltd’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$332K	Sell	1,344 -1,378	-51%	-$351K	0.01%	352
2026 Q2	$819K	Buy	2,722 +32	+1%	+$9.7K	0.01%	251
2026 Q1	$890K	Sell	2,690 -2,349	-47%	-$799K	0.01%	231
2025 Q4	$2M	Buy	+5,039	New	+$2.23M	0.03%	179
2025 Q2	–	Sell	-3,718	Closed	-$1M	–	418
2025 Q1	$1M	Sell	3,718 -5,213	-58%	-$1.34M	0.01%	243
2024 Q4	$2.1M	Buy	8,931 +4,819	+117%	+$1.27M	0.02%	191
2024 Q3	$1.13M	Buy	+4,112	New	+$1.07M	0.01%	250

Other funds holding ALNY

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return

Perpetual Ltd's ALNY Position: Q3 2026 in Review

Perpetual Ltd reduced its Alnylam Pharmaceuticals (ALNY) stake by 51% in Q3 2026, selling an estimated $351K and leaving 1,344 shares worth $332K. The position accounts for 0.01% of the portfolio, ranked #352.

Perpetual Ltd first reported a position in ALNY in Q3 2024 and has held it in 7 quarters since. The position peaked at $2.1M in Q4 2024. 328 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

Perpetual Ltd held 1,344 shares of Alnylam Pharmaceuticals worth $332K as of Q3 2026.
Perpetual Ltd sold 1,378 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $351K.
Alnylam Pharmaceuticals made up 0.01% of Perpetual Ltd's portfolio in Q3 2026, its #352 holding.
Perpetual Ltd first reported a position in Alnylam Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
Perpetual Ltd's Alnylam Pharmaceuticals position peaked at $2.1M in Q4 2024.
328 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on Perpetual Ltd's 13F filing for Q3 2026, filed 13 Oct 2026.